Protocol
Magnesium Glycinate 300–400 mg elemental
No randomized trial of magnesium glycinate alone has measured blood pressure.
Grade D, not yet tested: no human randomized trial has been run. This D records missing trials, not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The description presented about 2 mmHg as a general effect and carried two uncited claims (deficiency is common; red-cell magnesium is the more sensitive measure). Argeros et al. (Hypertension, 2025; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 41000008), 38 trials, is added: no significant effect in people with normal blood pressure, falls of 7.7 and 6.0 mmHg in treated hypertensives and people with low magnesium, no dose-response. The glycinate form remains untested on blood pressure, so D Route 1 stands; the reading says the class evidence would be B in hypertensive or magnesium-depleted adults and not in normotensive ones. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 41000008
The magnesium glycinate elemental protocol held a B on a meta-analysis of oral magnesium salts generally (Zhang et al., Hypertension 2016; PMID 27402922), which the record itself said did not test glycinate. EBL grades magnesium by the salt on the label. The only glycinate trial with a blood pressure outcome gave it with vitamin D (Cheung et al., Nutrition 2022; PMID 35576873). Untested for this salt: D on Route 1. This is not a finding that magnesium does not work. Editor adjudication, October 2026.PMID 27402922 PMID 35576873
Every change to a letter on this site is dated and published. The full evidence log →
This protocol is magnesium glycinate at 300 to 400 mg a day for blood pressure. No study has tested magnesium glycinate itself on blood pressure. Studies of other forms of magnesium found the top number about 2 points lower on average. Whether the glycinate form does the same has not been tested.
No randomized trial of magnesium glycinate alone has measured blood pressure. For oral magnesium salts pooled together, a 34-trial meta-analysis found systolic pressure about 2 mmHg lower (Zhang 2016; PMID 27402922) and a 2025 meta-analysis of 38 trials about 2.8 mmHg lower overall, with no significant effect in people with normal blood pressure and larger falls in treated hypertensives (7.7 mmHg) and people with low magnesium (6.0 mmHg) (Argeros 2025; PMID 41000008); the 2006 Cochrane review judged the effect weak and probably due to bias (PMID 16856052).
Why this gradeGrade D, not yet tested. The reasoning, and what the grade does not cover.
Grade D on Route 1 for blood pressure: no randomized trial has tested magnesium glycinate alone on blood pressure, and the PubMed search recorded on this record (October 2026) found none. The class evidence comes from other magnesium salts: a meta-analysis of 34 trials found systolic pressure about 2 mmHg lower (Zhang et al., 2016; PMID 27402922), a 2025 meta-analysis of 38 trials found about 2.8 mmHg lower overall with no significant effect in normotensive people and larger falls in treated hypertensives and people with low magnesium (Argeros et al., 2025; PMID 41000008), and a Cochrane review judged the small effect probably due to bias (Dickinson et al., 2006; PMID 16856052). Were the record graded on magnesium as a class it would be B for treated hypertensives and people with low magnesium, a replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. surrogate, and not for adults with normal pressure. The one glycinate trial combined it with vitamin D, and blood pressure fell only in a subgroup (Cheung et al., 2022; PMID 35576873).
WHAT THIS GRADE DOES NOT COVERmagnesium as a nutrient, magnesium deficiency, or other magnesium salts, which carry their own evidence. The D says the glycinate form has not been tested on this endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score., not that it was tested and failed.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
The evidence, in fullFour papers, each linked to its PubMed record.
Zhang et al. (Hypertension, 2016; PMID 27402922): meta-analysis of 34 trials of oral magnesium salts generally; systolic pressure about 2 mmHg lower; the trials did not test glycinate specifically. Argeros et al. (Hypertension, 2025; PMID 41000008): meta-analysis of 38 randomized trials, 2,709 participants, median 365 mg elemental for 12 weeks; systolic 2.81 and diastolic 2.05 mmHg lower overall, with no significant effect in normotensive people, larger falls in treated hypertensives and people with low magnesium, no dose-response and high heterogeneity How much the results of the pooled trials differ from each other. High heterogeneity makes a combined estimate less reliable.. Dickinson et al. (Cochrane Database Syst Rev, 2006; PMID 16856052): Cochrane review; the small blood pressure effect of magnesium was judged probably due to bias. Cheung et al. (Nutrition, 2022; PMID 35576873): randomized trial of magnesium glycinate combined with vitamin D; blood pressure fell only in a subgroup with higher baseline systolic pressure; it does not test glycinate alone.
Blood pressure at baseline and 8 weeks, which is what the pooled trials measured; in those trials the fall was about 2 to 3 mmHg systolic overall and larger in treated hypertensives and people with low magnesium (PMID 41000008). Serum magnesium if deficiency is suspected.
Evidence notes:
Endpoint graded: Blood pressure (surrogate)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →